Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Use of nonaspirin nonsteroidal anti-inflammatory drugs and risk of head and neck cancer: A nationwide case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Transcriptome-wide association study reveals candidate causal genes for lung cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Cervical cancer risk in women living with HIV across four continents: A multicohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Up to 60% of patients treated with cancer immunotherapy develop severe or life threatening immune-related adverse events (irAEs). Immunosuppression with high dose corticosteroids, or tumor necrosis factor (TNF) antagonists in refractory cases, is the mainstay of treatment for irAEs. It is currently unknown what impact corticosteroids and anti-TNF have on the activity of antitumor T cells. In our study, the influence of clinically relevant doses of dexamethasone (corresponding to an oral dose of 10-125 mg prednisolone) and infliximab (anti-TNF) on the activation and killing ability of tumor-infiltrating lymphocytes (TILs) was tested in vitro. Overall, dexamethasone at low or intermediate/high doses impaired the activation (-46 and -62%, respectively) and tumor-killing ability (-48 and -53%, respectively) of tumor-specific TILs. In contrast, a standard clinical dose of infliximab only had a minor effect on T cell activation (-20%) and tumor killing (-10%). A 72-hr resting period after withdrawal of dexamethasone was sufficient to rescue the in vitro activity of TILs, while a short withdrawal did not result in a full rescue. In conclusion, clinically relevant doses of infliximab only had a minor influence on the activity of tumor-specific TILs in vitro, whereas even low doses of corticosteroids markedly impaired the antitumor activity of TILs. However, the activity of TILs could be restored after withdrawal of steroids. These data indirectly support steroid-sparing strategies and early initiation of anti-TNF therapy for the treatment of irAEs in immuno-oncology.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cancer
Sider (fra-til)1408-1413
ISSN0020-7136
DOI
StatusUdgivet - 1 sep. 2019

ID: 56254027